PL3621694T3 - Inhibitory lrrc33 i ich zastosowanie - Google Patents

Inhibitory lrrc33 i ich zastosowanie

Info

Publication number
PL3621694T3
PL3621694T3 PL18727561.5T PL18727561T PL3621694T3 PL 3621694 T3 PL3621694 T3 PL 3621694T3 PL 18727561 T PL18727561 T PL 18727561T PL 3621694 T3 PL3621694 T3 PL 3621694T3
Authority
PL
Poland
Prior art keywords
lrrc33
inhibitors
lrrc33 inhibitors
Prior art date
Application number
PL18727561.5T
Other languages
English (en)
Inventor
Alan Buckler
Gregory J. Carven
Stefan WAWERSIK
Thomas SCHURPF
Constance MARTIN
Abhishek Datta
Mark Allen Farmer
Original Assignee
Scholar Rock, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock, Inc. filed Critical Scholar Rock, Inc.
Publication of PL3621694T3 publication Critical patent/PL3621694T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL18727561.5T 2017-05-09 2018-05-09 Inhibitory lrrc33 i ich zastosowanie PL3621694T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762503785P 2017-05-09 2017-05-09
US201762558048P 2017-09-13 2017-09-13
US201862663030P 2018-04-26 2018-04-26
US201862666182P 2018-05-03 2018-05-03
PCT/US2018/031759 WO2018208888A1 (en) 2017-05-09 2018-05-09 Lrrc33 inhibitors and use thereof

Publications (1)

Publication Number Publication Date
PL3621694T3 true PL3621694T3 (pl) 2024-02-05

Family

ID=62245483

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18727561.5T PL3621694T3 (pl) 2017-05-09 2018-05-09 Inhibitory lrrc33 i ich zastosowanie

Country Status (15)

Country Link
US (1) US20200181251A1 (pl)
EP (2) EP4286013A3 (pl)
JP (1) JP2020519579A (pl)
AU (1) AU2018266784C9 (pl)
DK (1) DK3621694T5 (pl)
ES (1) ES2958587T3 (pl)
FI (1) FI3621694T3 (pl)
HR (1) HRP20230742T1 (pl)
HU (1) HUE063120T2 (pl)
LT (1) LT3621694T (pl)
PL (1) PL3621694T3 (pl)
PT (1) PT3621694T (pl)
SI (1) SI3621694T1 (pl)
SM (1) SMT202300256T1 (pl)
WO (1) WO2018208888A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102776166B1 (ko) 2017-08-07 2025-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 안전한 세포 치료제를 생성하기 위한 플랫폼
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
CA3155172A1 (en) * 2019-10-25 2021-04-29 Shinko HAYASHI Combination of anti-garp antibody and immunomodulator
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
JP2025526336A (ja) 2022-07-22 2025-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
JP2026507882A (ja) 2023-03-07 2026-03-06 スカラー ロック インコーポレイテッド 患者の抵抗性又は不応答性癌を治療するためのＴＧＦ－β阻害剤及びその使用
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500704A (ja) 2012-11-06 2016-01-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 細胞シグナル伝達を変調するための組成物及び方法
SMT202100008T1 (it) 2013-05-06 2021-03-15 Scholar Rock Inc Composizioni e metodi per la modulazione di fattore di crescita
KR20250011248A (ko) 2016-03-11 2025-01-21 스칼러 락, 인크. TGFβ1-결합 이뮤노글로불린 및 그의 용도
EP3532494A4 (en) 2016-10-26 2020-06-03 The Children's Medical Center Corporation METHOD AND COMPOSITIONS FOR MODULATING TRANSFORMATION GROWTH FACTOR BETA-REGULATED FUNCTIONS

Also Published As

Publication number Publication date
DK3621694T5 (da) 2024-09-02
US20200181251A1 (en) 2020-06-11
SI3621694T1 (sl) 2023-10-30
JP2020519579A (ja) 2020-07-02
EP3621694A1 (en) 2020-03-18
FI3621694T3 (fi) 2023-08-28
CA3099260A1 (en) 2018-11-15
AU2018266784C1 (en) 2024-09-05
HUE063120T2 (hu) 2023-12-28
SMT202300256T1 (it) 2023-09-06
AU2018266784C9 (en) 2024-10-03
AU2018266784A1 (en) 2019-12-05
EP4286013A2 (en) 2023-12-06
EP3621694B1 (en) 2023-07-05
AU2018266784B2 (en) 2024-06-06
LT3621694T (lt) 2023-11-27
PT3621694T (pt) 2023-10-09
EP4286013A3 (en) 2024-02-28
ES2958587T3 (es) 2024-02-12
WO2018208888A1 (en) 2018-11-15
DK3621694T3 (da) 2023-09-11
HRP20230742T1 (hr) 2023-10-27

Similar Documents

Publication Publication Date Title
IL271999A (en) TYK2 inhibitors and uses thereof
IL265922A (en) tyk2 inhibitors and uses thereof
IL266109A (en) tyk2 inhibitors and uses thereof
IL282350A (en) Bernani-RGMC inhibitors and their use
IL270330B (en) Beta-lactamase inhibitors and their uses
ZA202002172B (en) Pde9 inhibitor and use thereof
IL272649B (en) AHR inhibitors and their uses
GB201605126D0 (en) Inhibitors and their uses
IL274504A (en) 2ACSS inhibitors and methods of their use
SG10201913927VA (en) Kinase inhibitors and uses thereof
SMT202300256T1 (it) Inibitori di lrrc33 e loro uso
HUE059778T2 (hu) URAT1-inhibitor és alkalmazása
GB201705138D0 (en) Method and use
SI3532459T1 (sl) Zaviralci LSD1 in njihove medicinske uporabe
IL267238A (en) The paranase inhibitors and their use
IL254916A0 (en) Inhibitors and their uses
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
IL267243A (en) The paranase inhibitors and their use
ZA201803212B (en) Gelatinase inhibitors and use thereof
IL274964A (en) Anti-chymase aptamer and its use
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
GB201705129D0 (en) Method and use
GB201705133D0 (en) Method and use
GB201705147D0 (en) Method and use
GB201505971D0 (en) Inhibitors and their uses